Arcellx is a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies. Its platform (ARC-SparX) underlies cell therapy candidates including CART-ddBCMA and ACLX-001/ACLX-002. CART-ddBCMA is a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 with a pivotal trial anticipated to begin in 2022. The company plans to use newly raised funds to develop CART-ddBCMA and to initiate clinical trials for ACLX-001 (multiple myeloma) and ACLX-002 (acute myelogenous leukemia). Financially, Arcellx completed a $115M Series C financing. The company is led by Chairman and CEO Rami Elghandour. Arcellx is a biopharmaceutical company developing an ARC-T + sparX intelligent cell therapy platform. The proprietary platform uses sparX soluble proteins to bind one or more tumor antigens and engage a universal receptor on engineered Antigen-Receptor Complex T cells (ARC-T), forming a sparX+ARC-T+tumor complex that mediates tumor killing. The company is advancing a pipeline that includes a bivalent BCMA-targeted ARC-T for multiple myeloma and a CD123-targeted therapy for acute myeloid leukemia, plus earlier-stage programs targeting solid tumors and diseases outside oncology. Arcellx positions the approach as improving safety and efficacy relative to conventional CAR-T therapies while broadening patient access and enabling scalable, efficient manufacturing. The company plans to begin clinical testing of its lead BCMA-targeted therapy in the coming months. Arcellx is based in Montgomery County, Maryland, and recently raised $85 million in a Series B to fund clinical and earlier-stage development.

Total raised

$200M

Funding rounds

2

Latest round

Series C

Latest activity

Apr 2021